Request Demo

Last update 06 Sep 2025

Gantenerumab

Last update 06 Sep 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Gantenerumab (genetical recombination) (JAN), Gantenerumab (USAN/INN), MAB-31

+ [4]

Target

APP

Action

inhibitors

Mechanism

APP inhibitors(Beta amyloid A4 protein inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication-

Inactive Indication

Alzheimer DiseasePain

Originator Organization

Chugai Pharmaceutical Co., Ltd.

Active Organization-

Inactive Organization

Hoffmann-La Roche, Inc.

Genentech, Inc.F. Hoffmann-La Roche Ltd.

+ [1]

License Organization

Roche Holding AG

Royalty Pharma Plc

MorphoSys AG

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

RegulationBreakthrough Therapy (United States)

Structure/Sequence

Sequence Code 65473H

Source: *****

Sequence Code 65501L

Source: *****

Clinical Trials associated with Gantenerumab

NCT05256134

/ TerminatedPhase 3

A Phase III, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease

A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD. The planned number of participants for this study is approximately 1200 participants randomized in a 1:1 ratio to receive either gantenerumab or placebo (600 participants randomized to gantenerumab and 600 participants randomized to placebo).

Start Date19 Apr 2022

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

CTR20210207

/ CompletedPhase 1

一项在健康中国受试者中考察单次腹部皮下注射GANTENERUMAB高浓度液体制剂后药代动力学、安全性和耐受性的单中心、开放性、I期研究

[Translation] A single-center, open-label, Phase I study investigating the pharmacokinetics, safety, and tolerability of a single subcutaneous abdominal injection of a high-concentration liquid formulation of GANTENERUMAB in healthy Chinese subjects

本研究将在健康中国受试者中评价G4工艺生产的gantenerumab在单次皮下注射510 mg剂量后的药代动力学、安全性和耐受性特征。 1. 药代动力学目的：根据以下终点，描述健康中国受试者单次SC注射（510 mg）gantenerumab的药代动力学特征： ● 主要PK参数：AUCinf和Cmax ● 次要PK参数：AUC0-672h、AUC0-last、t1/2（如下方法计算：ln 2/消除速率常数[λz]）、表观清除率（CL/F）、非静脉给药后的终末期分布容积（Vz/F） 2. 安全性目的根据以下终点，评价健康中国受试者单次SC注射（510 mg）gantenerumab的安全性和耐受性： ● 不良事件的性质、发生率、严重程度和因果关系 ● 使用视觉模拟量表（VAS）和言语评定量表（VRS）进行局部疼痛评估 ● 异常实验室检查结果、异常生命体征和异常心电图的发生率 ● ISR的发生率（局部和全身） 3. 免疫原性目的根据以下终点评价受试者对gantenerumab的免疫应答： ● 研究期间gantenerumab抗药抗体（ADA）发生率相对基线时ADA发生率的变化

[Translation]

This study will evaluate the pharmacokinetics, safety, and tolerability of gantenerumab produced by the G4 process after a single subcutaneous injection of 510 mg in healthy Chinese subjects. 1. Pharmacokinetics Objective: To describe the pharmacokinetic characteristics of a single SC injection (510 mg) of gantenerumab in healthy Chinese subjects based on the following endpoints: ● Primary PK parameters: AUCinf and Cmax ● Secondary PK parameters: AUC0-672h, AUC0-last, t1/2 (calculated as: ln 2/elimination rate constant [λz]), apparent clearance (CL/F), terminal distribution volume after non-intravenous administration (Vz/F) 2. Safety Objective To evaluate the safety and tolerability of a single SC injection (510 mg) of gantenerumab in healthy Chinese subjects based on the following endpoints: ● Nature, incidence, severity and causality of adverse events ● Local pain assessment using visual analogue scale (VAS) and verbal rating scale (VRS) ● Incidence of abnormal laboratory test results, abnormal vital signs and abnormal electrocardiogram ● Incidence of ISR (local and systemic) 3. Immunogenicity Objectives The immune response of subjects to gantenerumab was evaluated based on the following endpoints: ● Change in the incidence of gantenerumab anti-drug antibodies (ADA) during the study period relative to the baseline ADA incidence

Start Date02 Jun 2021

Sponsor / Collaborator

F. Hoffmann-La Roche Ltd.

[+1]

NCT04374253

/ TerminatedPhase 3

An Open-Label, Multicenter, Rollover Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease

This is an open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term administration of open-label gantenerumab in participants with AD who completed Study WN29922 or WN39658, either the double-blind or open-label extension (OLE) part.

Start Date26 Jan 2021

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

100 Clinical Results associated with Gantenerumab

100 Translational Medicine associated with Gantenerumab

100 Patents (Medical) associated with Gantenerumab

117

Literatures (Medical) associated with Gantenerumab

01 Aug 2025·LANCET NEUROLOGY

Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease.

Letter

Author: Zhang, Yang ; Shang, Huifang ; Zhang, Sirui ; Cheng, Yangfan

01 Aug 2025·LANCET NEUROLOGY

Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease - Authors' reply.

Letter

Author: Li, Yan ; Supnet, Charlene ; Bateman, Randall J ; Clifford, David B ; McDade, Eric M ; Llibre-Guerra, Jorge J ; Atri, Alireza

01 Aug 2025·LANCET NEUROLOGY

Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease.

Letter

Author: Walsh, Sebastian ; Richard, Edo ; Milne, Richard ; Brayne, Carol ; Howard, Robert

190

News (Medical) associated with Gantenerumab

04 Aug 2025

·www.einpresswire.com

Biomed Industries Presents Four Breakthrough Studies on Alzheimer’s, Rett Syndrome, and Obesity Therapies at AAIC 2025

Biomed Industries, Inc. Presents Four Pivotal Studies at AAIC 2025 Highlighting Breakthrough Therapies for Alzheimer’s, Rett Syndrome, and Obesity NA-831 is the only drug to date that has halted Alzheimer’s disease progression. Combining it with existing drugs like Donanemab could optimize therapeutic efficacy and reduce serious side effects.” — Dr. Lloyd L. Tran, CEO of Biomed SAN JOSE, CA, UNITED STATES, August 4, 2025 / EINPresswire.com / -- Biomed Industries, Inc., a leading biopharmaceutical innovator developing transformative therapies for neurological and metabolic diseases, today announced the presentation of four major scientific papers at the Alzheimer’s Association International Conference (AAIC), held July 27–31, 2025, in Toronto, Canada. The presentations featured Biomed’s next-generation oral therapies for Alzheimer’s disease, Rett syndrome, and obesity, with a focus on novel combination strategies designed to enhance safety, efficacy, and accessibility. Featured AAIC 2025 Presentations: 1. The End of the Amyloid Era? Evidence for a Paradigm Shift in the Quest to Treat Alzheimer’s Disease 2. A Phase 3 Clinical Protocol of NA-831 Combined with Donanemab in Early Alzheimer’s Disease: A Placebo-Controlled, Double-Blind Study 3. Associations Between Alzheimer’s Disease and Rett Syndrome: Clinical Trials of NA-831 and NA-921 4. Neuro-Metabolic Link Between Alzheimer’s Disease and Obesity: Clinical Evaluation of NA-831 and NA-931 1. PRESENTATION: The End of the Amyloid Era? A Paradigm Shift in Alzheimer’s Research For over three decades, the “amyloid hypothesis” has dominated Alzheimer’s disease (AD) research, asserting that amyloid-β accumulation is a primary driver of neurodegeneration. Biomed’s comprehensive analysis of Phase 3 trial data from seven anti-amyloid drugs — including aducanumab, lecanemab, donanemab, gantenerumab, bapineuzumab, crenezumab, and solanezumab — challenges this paradigm. Across all trials, both treatment and placebo groups exhibited similar cognitive decline, as measured by CDR-SB and ADAS-Cog. The average differences between treatment and placebo arms were minor and not clinically significant (CDR-SB: -0.25; ADAS-Cog: -0.79). Slope comparisons further revealed near-identical rates of decline between groups. “Our analysis of Phase 3 clinical trial data for seven anti-amyloid drugs, including FDA-approved Aducanumab, Lecanemab, and Donanemab, indicates that none could halt disease progression in a clinically meaningful way — and all carried serious safety concerns,” said Dr. Zung Tran, VP of Biostatistics and AI at Biomed. 2. PRESENTATION: Phase 3 Clinical Protocol of NA-831 Combined with Donanemab NA-831, Biomed’s lead oral candidate, is a first-in-class therapy that promotes neuroprotection, neurogenesis, and memory enhancement. Phase 2 trials demonstrated its disease-modifying potential with a favorable safety profile compared to traditional anti-amyloid drugs. In this upcoming Phase 3 study, NA-831 will be evaluated in combination with Donanemab, a recently FDA-approved monoclonal antibody, to explore synergistic effects. The goal is to lower Donanemab dosing, thereby reducing risks such as cerebral edema and microbleeds, while enhancing cognitive outcomes. “NA-831 is the only drug to date that has halted disease progression in Phase 2 trials,” said Dr. Lloyd Tran, CEO of Biomed Industries. “Combining it with existing drugs like Donanemab could optimize therapeutic efficacy and reduce serious side effects.” 3. PRESENTATION: Alzheimer’s and Rett Syndrome: Shared Mechanisms and Dual Therapeutic Potential Biomed also presented findings on NA-921, a structural analog of NA-831 developed for Rett syndrome, a rare X-linked neurodevelopmental disorder. NA-921 modulates MeCP2 expression, targeting the disorder’s core epigenetic dysfunction. A double-blind, placebo-controlled Phase 2/3 trial (ClinicalTrials.gov ID: NCT06849973) demonstrated promising results: Clinical Global Impression–Improvement (CGI-I) at week 12: NA-921: 3.60 | Placebo: 3.83 | P = 0.0020 | Effect size = 0.42 NA-921 was well tolerated, with a significantly improved safety profile compared to trofinetide: - Diarrhea: Trofinetide 82%, NA-921 24%, Placebo 19% - Vomiting: Trofinetide 29%, NA-921 9%, Placebo 11% - Fever: Trofinetide 9%, NA-921 5%, Placebo 4% These findings underscore a possible biological link between Alzheimer’s disease and Rett syndrome, opening new cross-indication opportunities for NA-831 and NA-921. 4. PRESENTATION: Neuro-Metabolic Connections: NA-831 and NA-931 in Alzheimer’s and Obesity Biomed’s data also revealed compelling evidence of a neuro-metabolic bridge between Alzheimer’s disease, diabetes, and obesity. In addition to NA-831’s CNS benefits, Biomed is advancing NA-931, an oral quadruple receptor agonist (IGF-1, GLP-1, GIP, and glucagon) designed to treat obesity. In a 13-week Multiple Ascending Dose (MAD) study: - Mean body weight reduction: Up to 13.8% at 150 mg daily, 12.4% greater than placebo - ≥12% weight loss achieved by 72% of NA-931-treated patients vs. 2% in placebo group NA-931 demonstrated a strong safety profile, with mild and transient GI-related adverse events, and no observed muscle loss. “Our pipeline shows how targeting interconnected pathways across the CNS and metabolic systems can unlock significant clinical potential,” said Michael Willis, VP of Business Development. “With six active programs across Alzheimer’s, ALS, Rett syndrome, stroke, obesity, and MASH, we are building a diversified platform to accelerate innovation and value creation.” ABOUT BIOMED INDUSTRIES, INC. Biomed Industries, Inc. is a pioneering biopharmaceutical company committed to developing novel therapeutics that address unmet medical needs. Its innovative research platform has produced treatments for conditions including Alzheimer’s disease, ALS, Traumatic Brain Injury, Major Depressive Disorder, Diabetes, Obesity, MASH, Stroke, and rare diseases such as Huntington Disease and Rett Syndrome. (Website: https://www.biomedind.com ) Michael Willis Biomed Industries, Inc. email us here Visit us on social media: LinkedIn X Biomed introduction video Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical ResultPhase 2Phase 3

28 Jul 2025

·endpoints.news

Roche doubles down on its Alzheimer's ambitions as next-gen amyloid-lowering drug excites scientists

TORONTO — Three years after a disappointing clinical failure cast doubts on Roche’s future in Alzheimer’s disease, the company is going all in on a sequel program. And early data suggest it might be the most potent amyloid-clearing drug yet. In a packed room at the Alzheimer’s Association International Conference in Toronto on Sunday, Roche revealed the latest cut of data from its closely-watched Phase 1/2 study of trontinemab, an amyloid-targeting antibody designed to latch onto receptors that yank it across the protective blood-brain barrier. Unlike its failed predecessor gantenerumab, which only slowly and modestly reduced amyloid plaques over two years, trontinemab practically eliminated amyloid in just seven months. One patient died from a brain hemorrhage early in their treatment, causing Roche to tighten its criteria last year to exclude participants who are susceptible to the fatal side effect. Aside from that fatality, trontinemab actually appeared to cause far less frequent and less severe cases of brain bleeding and swelling than Leqembi and Kisunla, the amyloid antibodies sold by Eisai/Biogen and Eli Lilly, respectively. (The study did not compare trontinemab against those therapies.) At the meeting, scientists say they are eager to see if the finding holds up in bigger studies. “I could barely contain myself from jumping up and whooping,” Reisa Sperling, director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital, said during a panel following Roche’s presentation. Roche’s new study doesn’t prove that removing amyloid helps patients, and the company cautioned that it was not big enough or long enough to do so. But a pair of 800-person studies that it plans to begin later this year may help answer that question. Those Phase 3 studies, the design of which was outlined for the first time on Sunday, will test the drug in people with early Alzheimer’s for 18 months. Roche also announced its intention to test trontinemab in people with so-called “preclinical Alzheimer’s” who have amyloid buildup in the brain but are not yet showing signs of memory loss. The approach could more dramatically stall, and possibly prevent, the disease. Eisai and Lilly are conducting similar prevention studies with their drugs. “We are excited about this program and the potential benefit that it might bring to patients with Alzheimer’s disease. That is very clear,” Luka Kulic, Roche’s global head of early development for neuroscience and rare diseases, told Endpoints News in an interview. “This commitment has never stopped, even after the setback.” Trontinemab is a bispecific antibody that combines gantenerumab with a new molecule dubbed a Brainshuttle that binds to transferrin receptors along the border of the protective blood-brain barrier. Roche believes that getting more of the drug into the brain more quickly could help overcome gantenerumab’s prior failure. “What we learned over the past couple of years is that it’s not just about targeting amyloid; it’s really about getting it substantially low,” Kulic said. In new data from 54 patients who got the 3.6 mg/kg dose of trontinemab — the highest dose in the current study and the one Roche plans to use in its upcoming Phase 3 studies — 91% of patients became “amyloid negative” on brain scans within 28 weeks based on a common threshold of 24 centiloids, a PET measurement that represents minimal plaques in the brain. In the upcoming Phase 3 studies, patients will get an infusion of trontinemab every four weeks for 24 weeks before switching to a “maintenance regimen,” during which they get the infusion every 12 weeks. Eisai’s drug, in contrast, is administered once or twice a month indefinitely. Lilly recommends that patients stop receiving its monthly drug after becoming amyloid negative on a PET scan. Roche hopes to avoid that requirement for additional PET scans. Jessica Langbaum, senior director of research strategy at the Banner Alzheimer’s Institute, was encouraged by trontinemab’s dramatic and rapid amyloid reduction as well as the low rates of side effects like brain bleeding and swelling, which she said “could be tremendously helpful” for use as a preventative therapy. “What’s most exciting was the energy in the room,” Langbaum told Endpoints. “The field was in despair. We have this hope now.” It’s unclear if more powerful amyloid removal is safer or more dangerous. Lilly recently found that ramping up the dose of its drug more slowly lowered the risk of brain swelling, known as amyloid-related imaging abnormality with edema or effusion, or ARIA-E. Some scientists wondered if trontinemab’s rapid amyloid reduction would backfire. “I was a little bit worried. I was thinking that if you do this very intensely, then perhaps you will get neurotoxicity,” Henrik Zetterberg, professor of neuroscience at Sweden’s University of Gothenburg who is involved in the trontinemab studies, told Endpoints. “And that didn’t happen. So I feel like this is looking good.” ARIA-E occurred in 3.9% of patients who got the 1.8 mg/kg dose and 1.4% of patients who got the 3.6 mg/kg dose, compared to 13% of patients in Eisai’s registrational study and 14% of patients in Lilly’s recent study that adjusted dosing to lower ARIA-E. Signs of brain bleeding, known as ARIA with hemosiderin or hemorrhage, or ARIA-H, occurred in 6.6% and 2.7% of patients on the lower and higher doses of trontinemab, respectively, compared with 17% of patients in Eisai’s registrational study and 20% of patients in Lilly’s recently updated dosing study. It is unclear why both forms of ARIA were more prevalent in patients receiving the smaller of two doses of trontinemab. Kulic said the difference could be due to chance, given the relatively small size of the study. But he added that “it’s reassuring” that ARIA wasn’t more common in patients who received the higher dose. The otherwise promising results were marred by the death of a 78-year-old woman who suffered a brain hemorrhage — a known risk of the drug class — six weeks into the study. An MRI scan during screening revealed that the woman had a spot of abnormal iron accumulation known as superficial siderosis that is indicative of prior bleeding and is a risk factor for ARIA. Roche previously reported the death at an Alzheimer’s conference in 2024. Kulic said the death caused Roche to tighten its “relatively relaxed” criteria for the study and prevent people with superficial siderosis from getting the drug.

Phase 3Clinical Result

28 Jul 2025

·www.biospace.com

Roche’s Next-Gen Alzheimer’s Antibody Clears or Reduces Amyloid Plaques in Seven Months

iStock, Massonstock In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift” to first-generation FDA-approved antibodies. Roche touted rapid amyloid clearance from the brains of patients with Alzheimer’s disease after treatment with its anti-amyloid antibody trontinemab on Sunday. In a highly anticipated presentation at the Alzheimer’s Association International Conference 2025 in Toronto, Roche revealed data from its ongoing Phase Ib/IIa Brainshuttle AD trial. In the dose-expansion section of the study, 91% of patients (49 of 54) who received the higher dose level of trontinemab, 3.6 mg/kg, were amyloid negative on a PET scan after seven months of treatment, while 72% (39 patients) saw “deep clearance” of plaques, as rated on a common plaque deposit measuring scale. Analysts at B. Riley Securities on Monday wrote that the data “represents a paradigm shift” to first-generation FDA-approved antibodies, specifically noting Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla. Noting that treatment with trontinemab led to a “90%+ reduction from baseline with nearly all trontinemab -treated patients responding,” the analysts said this level and speed of clearance beat out what Leqembi and Kisunla achieved even after 18 plus months of treatment. The Brainshuttle AD results come more than five years after Roche’s previous attempt at an Alzheimer’s antibody, gantenerumab, fell flat. In February 2020, Roche’s Genentech reported that gantenerumab missed the primary endpoint of a Phase III trial and the company halted development. Safety was also a highlight for Roche this time around. Amyloid-related imaging abnormalities (ARIAs), signifying brain lesions or swelling, are a known risk of anti-amyloid antibodies. Four of the total 149 patients treated with trontinemab across all doses had ARIAs. These abnormalities have dogged Biogen’s and Lilly’s drugs, reaching rates into the teens in tested patients with Leqembi . The news wasn’t all rosy though— Endpoints News reported that one trial participant, a 78-year-old woman, died of a brain hemorrhage. Her death occurred six weeks into the study. A scan of her brain showed an abnormal accumulation of iron called superficial siderosis that is a risk factor for ARIA, according to the publication. Though the data from this trial do not signify an actual ability to treat Alzheimer’s disease or reduce symptoms, the results are significant enough to validate other companies’ therapeutic approaches, according to B. Riley. Trontinemab’s mechanism of action combines an antibody’s ability to bind amyloid with the capacity to bind a transferrin receptor shuttle module, allowing it to more ably cross the blood-brain barrier and penetrate into the brain. The Brainshuttle trial success de-risks companies like Denali and Cognition , according to the B. Riley analysts. Both companies are targeting neurodegenerative diseases—including Alzheimer’s, Parkinson’s and Hunter syndrome—with tech to better ferry drugs into the brain. In Sunday’s press release Roche also announced plans for two Phase III trials, TRONIER 1 and 2, to start sometime in 2025. Those trials will focus on patients at risk of cognitive decline, aiming to slow or prevent Alzheimer’s disease progression.

Phase 3Clinical Result

100 Deals associated with Gantenerumab

External Link

KEGG	Wiki	ATC	Drug Bank
D09713	Gantenerumab	-	DB12034

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	Argentina	Hoffmann-La Roche, Inc.	30 Nov 2010
Alzheimer Disease	Phase 3	Chile	Hoffmann-La Roche, Inc.	30 Nov 2010
Alzheimer Disease	Phase 3	Czechia	Hoffmann-La Roche, Inc.	30 Nov 2010
Alzheimer Disease	Phase 3	Finland	Hoffmann-La Roche, Inc.	30 Nov 2010
Alzheimer Disease	Phase 3	Mexico	Hoffmann-La Roche, Inc.	30 Nov 2010
Alzheimer Disease	Phase 3	Netherlands	Hoffmann-La Roche, Inc.	30 Nov 2010
Alzheimer Disease	Phase 3	Poland	Hoffmann-La Roche, Inc.	30 Nov 2010
Alzheimer Disease	Phase 3	Portugal	Hoffmann-La Roche, Inc.	30 Nov 2010
Alzheimer Disease	Phase 3	Sweden	Hoffmann-La Roche, Inc.	30 Nov 2010
Alzheimer Disease	Phase 3	Switzerland	Hoffmann-La Roche, Inc.	30 Nov 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01760005 \| NCT06424236 (DIAN-TU-001, Pubmed) Manual	Phase 2/3	Alzheimer Disease	74	gantenerumab (any gantenerumab)	aahhbqbads(unrbyepihm) = At the interim analysis, the hazard ratio for clinical decline of CDR-SB in asymptomatic mutation carriers was 0·79 (n=53 [95% CI 0·47 to 1·32]) for participants who were treated with gantenerumab in either the double-blind or OLE period (Any Gant), and 0·53 (n=22 [0·27 to 1·03]) for participants who were treated with gantenerumab the longest (Longest Gant). hcoyjvtlug (nzsklokjkm ) View more	Positive	01 Apr 2025
				gantenerumab (Longest gantenerumab)
NCT06424236 (DIAN-TU, CTgov)	Phase 2/3	Alzheimer Disease	73	OLE+Gantenerumab (Double-blind Placebo - OLE Gantenerumab)	pdhuajudoo(rfluxhbbkv) = khdrtopwea lgazbpvqzc (uptjcbutho, 0.22606) View more	-	04 Feb 2025
				Gantenerumab+Solanezumab (Double-blind Solanezumab - OLE Gantenerumab)	pdhuajudoo(rfluxhbbkv) = dsjrhirvvq lgazbpvqzc (uptjcbutho, 0.40538) View more
NCT03443973 \| NCT03444870 \| NCT04374253 (GRADUATE I/II, Pubmed \| JAMA Neurol)	Phase 3	Alzheimer Disease Fazekas score \| total superficial siderosis count \| total microhemorrhage count ... View more	1,939	Gantenerumab	mjxkowdmfq(djoljpeypz) = cpmfltwzic qehxachbem (izacgyzvjn ) View more	Positive	18 Nov 2024
NCT05256134 (SKYLINE, CTgov)	Phase 3	Alzheimer Disease	25	Placebo (Placebo)	wjvvljkowc(gczhiqccvt) = yqawtmkffl ytwxwrzcoh (ritgygxtml, 0.5790) View more	-	09 Jul 2024
				Gantenerumab (Gantenerumab)	wjvvljkowc(gczhiqccvt) = bvpjbonmgp ytwxwrzcoh (ritgygxtml, 0.6038) View more
NCT04374253 (CTgov)	Phase 3	Alzheimer Disease	1,382	Placebo (Placebo: Participated in Graduate OLE)	bbgtoyhqci = ofmmqudfjr vbvaadfpyl (xzluhpadzq, qtxzmgaszk - yrmyeisdbj) View more	-	08 May 2024
				Placebo (Placebo: No Participation in Graduate OLE)	bbgtoyhqci = hznibuvcqk vbvaadfpyl (xzluhpadzq, tnjmcnmcjk - slenqonvhm) View more
NCT04623242 (Pubmed)	Phase 2/3	Alzheimer Disease	-	Solanezumab	qogwfeppqs(wcqdwkxnjn) = ogohedjlkv zlcflhpmnu (eslrcpoxvo, 0.43)	-	29 Apr 2024
NCT04592341 (CTgov)	Phase 2	Alzheimer Disease	192	Gantenerumab	ksdgvxvyij(lfczolghwd) = tthhcmardu rjxirbshbq (ngpkfjjbiq, 29.80) View more	-	27 Mar 2024
NCT03444870 (CTgov)	Phase 3	Alzheimer Disease	1,053	placebo+gantenerumab (Global - DBT Period: Placebo)	gadzsfuovo(povbcyoubp) = juiiqdxvrj exvooatvfm (jmamarteck, 0.16) View more	-	30 Jan 2024
				Gantenerumab (Global - DBT Period: Gantenerumab)	gadzsfuovo(povbcyoubp) = xyzdipasyc exvooatvfm (jmamarteck, 0.14) View more
NCT04339413 (CTgov)	Phase 3	Alzheimer Disease	116	Gantenerumab (SCarlet RoAD)	pydntubqss = xbowxkyhkt odxqzqkdce (sabmxlxlob, wsnjlcaere - mzwasnfamm) View more	-	18 Jan 2024
				Gantenerumab (Marguerite RoAD)	pydntubqss = klfqmuzcnn odxqzqkdce (sabmxlxlob, tokvsrfdeb - ppfnlefofv) View more
NCT03443973 (CTgov)	Phase 3	Alzheimer Disease	975	placebo+gantenerumab (Placebo: DBT)	wekqazixsb(cfognfoggt) = odcnusaqhp uclneprnzz (jmtbcozbcy, 0.15) View more	-	17 Jan 2024
				Gantenerumab (Gantenerumab: DBT)	wekqazixsb(cfognfoggt) = zjiyeyiuwq uclneprnzz (jmtbcozbcy, 0.14) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis